Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EPS (Weighted Average and Diluted) (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.18 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 40.0% to -$0.18 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.0, a 13.04% increase, with the full-year FY2025 number at -$1.0, up 12.28% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.18 for Q4 2025 at TScan Therapeutics, up from -$0.28 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $10.88 in Q4 2021 to a low of -$7.69 in Q2 2021.
  • A 5-year average of -$0.2 and a median of -$0.3 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 141.56% in 2023, then tumbled 193.75% in 2024.
  • TScan Therapeutics' EPS (Weighted Average and Diluted) stood at $10.88 in 2021, then crashed by 107.08% to -$0.77 in 2022, then skyrocketed by 141.56% to $0.32 in 2023, then crashed by 193.75% to -$0.3 in 2024, then skyrocketed by 40.0% to -$0.18 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's EPS (Weighted Average and Diluted) are -$0.18 (Q4 2025), -$0.28 (Q3 2025), and -$0.28 (Q2 2025).